Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReaLuP re-treatment with Pluvicto in metastatic castration-resistant prostate cancer
2024-512043-22-00Phase 2Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hospices Civils de Lyon. Primary endpoint: Radiological progression-free survival at 24 weeks. Planned start Apr 2025; status: authorised.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-512043-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512043-22-00.